LIPOSORBER® LA-15 ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
222一次性ネフローゼ症候群2

222. 一次性ネフローゼ症候群

臨床試験数 : 285 /  薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04065438
(ClinicalTrials.gov)		January 1, 202020/8/2019Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 SystemTreatment of Drug-resistant Adult Primary Focal Segmental Glomerulosclerosis and Post -Transplant Recurrence Using the LIPOSORBER® LA-15 SystemFocal Segmental GlomerulosclerosisDevice: LIPOSORBER® LA-15Kaneka Medical America LLCNULLRecruiting22 Years75 YearsAll35N/AUnited States
2NCT02235857
(ClinicalTrials.gov)		March 20156/9/2014Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenTreatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 SystemFocal Segmental GlomerulosclerosisDevice: LIPOSORBER® LA-15 SystemKaneka Medical America LLCNULLRecruitingN/A21 YearsAll35N/AUnited States